Sterling Financial Planning Inc. cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.9% in the first quarter, HoldingsChannel reports. The fund owned 1,692 shares of the medical instruments supplier’s stock after selling 50 shares during the period. Sterling Financial Planning Inc.’s holdings in Becton, Dickinson and were worth $411,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in BDX. Flagship Private Wealth LLC acquired a new position in Becton, Dickinson and during the fourth quarter worth $25,000. Kempen Capital Management N.V. purchased a new position in shares of Becton, Dickinson and in the 4th quarter valued at about $29,000. Sage Private Wealth Group LLC purchased a new position in shares of Becton, Dickinson and in the 4th quarter valued at about $37,000. Fort Pitt Capital Group LLC purchased a new position in shares of Becton, Dickinson and in the 4th quarter valued at about $38,000. Finally, Mcmillion Capital Management Inc. acquired a new stake in shares of Becton, Dickinson and in the 4th quarter valued at about $40,000. 83.22% of the stock is owned by institutional investors.

Several analysts have recently commented on BDX shares. Raymond James raised their price target on Becton, Dickinson and from $270.00 to $282.00 and gave the company an “outperform” rating in a report on Friday, January 29th. Piper Sandler lifted their price objective on Becton, Dickinson and from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 4th. Citigroup lifted their price objective on Becton, Dickinson and from $273.00 to $280.00 and gave the company a “neutral” rating in a research report on Friday, February 5th. Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 target price on the stock. in a report on Wednesday, January 13th. Finally, TheStreet upgraded Becton, Dickinson and from a “c+” rating to an “a-” rating in a research note on Thursday, February 4th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $281.08.

BDX traded down $2.57 during trading on Tuesday, reaching $250.55. The stock had a trading volume of 5,115 shares, compared to its average volume of 1,312,288. The firm has a market capitalization of $72.80 billion, a price-to-earnings ratio of 92.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79. The company has a quick ratio of 1.07, a current ratio of 1.54 and a debt-to-equity ratio of 0.72. Becton, Dickinson and Company has a 1-year low of $219.50 and a 1-year high of $284.97. The stock has a 50 day moving average of $247.90 and a two-hundred day moving average of $246.48.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $1.41. The firm had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $4.87 billion. Becton, Dickinson and had a return on equity of 13.30% and a net margin of 5.11%. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.65 earnings per share. On average, research analysts forecast that Becton, Dickinson and Company will post 12.5 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 30th. Stockholders of record on Wednesday, June 9th will be given a dividend of $0.83 per share. The ex-dividend date is Tuesday, June 8th. This represents a $3.32 dividend on an annualized basis and a dividend yield of 1.33%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 32.55%.

About Becton, Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: What is operating income?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.